Vineet Laboratories Limited
Healthcare›Healthcare›Pharmaceuticals & Biotechnology›Pharmaceuticals
Key metrics
Price as of 2026-04-29
Sign in for full ratios and TTM. Learn about these metrics →
Share price
NSE closing price from historical market data.
Loading price history…
Statement tables · Consolidated
Switches quarterly, P&L, balance sheet, and cash flow. Key metrics and ratios stay on consolidated when available.
Amounts in ₹ Cr · NSE preferred when both exchanges report the same period · tap + to expand rows
Quarterly results
Quarterly · ₹ Cr · tap + rows to expand
| Metric | Mar 2025 | Jun 2025 | Sept 2025 |
|---|---|---|---|
| Sales | 14 Cr | 7 Cr | 17 Cr |
| Operating expenses (approx.) | 24 Cr | 7 Cr | 14 Cr |
| EBITDA | -10 Cr | 0.34 Cr | 3 Cr |
| OPM % | -68.7% | 4.5% | 18.3% |
| Other income | 1 Cr | 0.02 Cr | 0.0084 Cr |
| Interest | 0.90 Cr | 0.61 Cr | 2 Cr |
| Depreciation | 0.66 Cr | 0.63 Cr | 0.63 Cr |
| Profit before tax | -11 Cr | -0.90 Cr | 0.37 Cr |
| Tax % | 6.2% | 3.9% | -7.9% |
| Net profit | -11 Cr | -0.87 Cr | 0.40 Cr |
| EPS (₹) | ₹-11.42 | ₹-0.94 | ₹0.43 |
Profit & loss (annual)
Annual · last column is TTM · ₹ Cr · tap + to expand
| Metric | Mar 2025 | TTM |
|---|---|---|
| Sales | 75 Cr | Sign in for TTM |
| Operating expenses (approx.) | 89 Cr | Sign in for TTM |
| EBITDA | -14 Cr | Sign in for TTM |
| OPM % | -19.1% | Sign in for TTM |
| Other income | 2 Cr | Sign in for TTM |
| Interest | 4 Cr | Sign in for TTM |
| Depreciation | 3 Cr | Sign in for TTM |
| Profit before tax | -21 Cr | Sign in for TTM |
| Tax % | 2.8% | Sign in for TTM |
| Net profit | -20 Cr | Sign in for TTM |
| EPS (₹) | ₹-21.90 | Sign in for TTM |
| Dividend payout % | — | Sign in for TTM |
Trailing twelve months totals and margin rows
Balance sheet
Annual · ₹ Cr · tap + rows to expand
| Metric | Mar 2025 |
|---|---|
| Equity capital | 9 Cr |
| Reserves | 5 Cr |
| Borrowings | 36 Cr |
| Other liabilities | 44 Cr |
| Total liabilities | 95 Cr |
| Fixed assets (net) | 25 Cr |
| CWIP | — |
| Investments | 0.0000 Cr |
| Other assets | 67 Cr |
| Total assets | 95 Cr |
Cash flows
Annual · ₹ Cr · tap + rows to expand · last column includes FCF
| Metric | Mar 2025 |
|---|---|
| Cash from operating activity | 11 Cr |
| Cash from investing | -3 Cr |
| Cash from financing | -8 Cr |
| Net cash flow | 0.08 Cr |
| Free cash flow (OCF − Capex) | 10 Cr |
Ratios
Ratios as reported or derived per annual period.
| Metric | Mar 2025 |
|---|---|
| ROCE % | -33.0% |
| ROE % | -137.8% |
| Debtor days | — |
| Inventory days | 285 |
| Days payable | — |
| Cash conversion cycle | 285 |
| Debt / equity | 2.48 |
| Current ratio | 0.91 |
| Net debt / EBITDA | — |
Compare with peers
Loading peers…